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Abstract
Background: Metformin, an oral biguanide traditionally used for the treatment of type 2 diabetes, is widely used
for the management of polycystic ovary syndrome (PCOS)-related anovulation. Because of the significant
prevalence of insulin resistance and glucose intolerance in PCOS patients, and their putative role in ovulatory
dysfunction, the use of metformin was touted as a means to improve ovulatory function and reproductive
outcomes in PCOS patients. To date, there has been inconsistent evidence to demonstrate a favorable effect of
metformin on oocyte quality and competence in women with PCOS. Given the heterogeneous nature of this
disorder, we hypothesized that metformin may be beneficial in mice with aberrant metabolic characteristics similar
to a significant number of PCOS patients. The aim of this study was to gain insight into the in vitro and in vivo
effects of metformin on oocyte development and ovulatory function.
Methods: We utilized metformin treatment in the transgenic ob/ob and db/db mutant murine models which
demonstrate metabolic and reproductive characteristics similar to women with PCOS. Results: Metformin did not
improve in vitro oocyte maturation nor did it have an appreciable effect on in vitro granulosa cell luteinization
(progesterone production) in any genotype studied. Although both mutant strains have evidence of
hyperandrogenemia, anovulation, and hyperinsulinemia, only db/db mice treated with metformin had a greater
number of mature oocytes and total overall oocytes compared to control. There was no observed impact on body
mass, or serum glucose and androgens in any genotype.
Conclusions: Our data provide evidence to suggest that metformin may optimize ovulatory performance in mice
with a specific reproductive and metabolic phenotype shared by women with PCOS. The only obvious difference
between the mutant murine models is that the db/db mice have elevated leptin levels raising the questions of
whether their response to metformin is related to elevated leptin levels and/or if a subset of PCOS women with
hyperleptinemia may be responsive to metformin therapy. Further study is needed to better define a subset of
women with PCOS that may be responsive to metformin.
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Polycystic ovarian syndrome (PCOS) is a complex, multi-
factorial endocrinopathy which affects approximately 4 to
10% of reproductive-aged women. Because it is a highly
heterogeneous syndrome with a variable clinical presenta-
tion, criteria for diagnosis have been debated. Many autho-
rities utilize the guidelines of Rotterdam/ASRM-sponsored
PCOS Consensus Workshop Group [1] and require the
presence of at least two of the following: oligoovulation
and/or anovulation, evidence of clinical or biochemical
hyperandrogenism, and the presence of polycystic ovarian
morphology during ultrasound examination.
PCOS is associated with several significant morbidities
including infertility, obesity, insulin resistance, type 2 dia-
betes, dyslipidemia, and endometrial hyperplasia [2-6].
Proposed etiologies for PCOS include hypothalamic-pitui-
tary dysynchrony, aberrant gonadotropin pulsatile secre-
tion, granulosa/theca cell dysfunction, and various
metabolic derangements including exaggerated ovarian
androgen production, hyperinsulinemia, and insulin resis-
tance [7-12]. Still, it is unclear whether the primary source
of metabolic derangement is ovarian, hypothalamic/pitui-
tary, or a combination of several systemic factors.
Several therapeutic options have been utilized to treat
PCOS associated ovulatory dysfunction and infertility.
These include weight loss, clomiphene citrate, exogen-
ous gonadotropins, insulin sensitizers, and ovarian dia-
thermy. Since its introduction as a treatment for type 2
diabetes in the United States in 1996, metformin also
emerged as a common treatment for infertile women
with PCOS [13-15]. Despite widespread and continued
use, the efficacy of metformin as a treatment for PCOS
remains unproven and controversial. Metformin has
been shown by some investigators to result in weight
loss, normalization of menstrual cycles, and an improve-
ment of conception rates following therapies such as
ovulation induction and controlled ovarian hyperstimu-
lation prior to in vitro fertilization (IVF) [16-19]. In con-
trast, other studies have demonstrated that metformin
does not offer any clinical benefit [20-22].
Metformin has been primarily characterized as an acti-
vator of AMP activated kinase (AMPK) [23]. AMPK
serves as a sensor of energy status at the cellular level
and is activated by an elevated AMP/ATP ratio. Activa-
tion of AMPK may induce catabolic processes which gen-
erate ATP and reduce anabolic processes which consume
ATP. It can also serve as an energy sensor in several
organs. For example, small decreases in glucose result in
AMPK activation and decreased pancreatic insulin pro-
duction with increase hypothalamic-driven feeding beha-
vior [12,24-27]. Moreover, AMPK has evolved in higher
organisms to be a highly complex regulator of cytokine
function where leptin and adiponectin activate AMPK in
muscle to increase glucose uptake and fatty acid oxida-
tion [28,29]. The significance of metformin’sr o l ea sa n
AMPK modulator is uncertain in reproductive processes
such as oocyte maturation, ovulation, and luteinization.
To date, there is limited evidence demonstrating a con-
sistent physiologic effect of metformin on oocyte devel-
opment, ovulatory function, and fecundity in animal
models. Previous data in the bovine model have demon-
strated that metformin results in inhibition of maturation
of denuded (DO) and non denuded oocytes. A similar
effect was seen with a specific AMPK activator (AICAR),
implying that metformin’s inhibitory action may be
mediated in part by AMPK activation in the oocyte [30].
Similarly, in vitro studies using porcine oocytes have
shown that metformin prevents the maturation of the
oocyte when it is part of the cumulus oophorus complex
(COC). However, it did not prevent maturation of the
porcine DO [31]. The AMPK activator, AICAR, has been
shown to induce meiotic resumption in both mouse DO
and COC in vitro, whereas this effect is blocked by Com-
pound C, a specific AMPK inhibitor [32]. Metformin has
also been shown to inhibit progesterone production in
vitro through an AMPK mediated pathway in a number
of cell types derived from several different species
[33-35]. Notably, in vitro metformin concentrations of all
aforementioned studies were supraphysiologic (0.1 - 2
mM). According to Lee and Kwon [36], serum concen-
trations in physiologic doses in humans are much lower,
at approximately 8 - 10 μM.
Given the inconsistent results of published bovine and
murine studies, and the controversy surrounding metfor-
min’s efficacy in PCOS-related ovulatory dysfunction and
infertility, the goal of this study was to gain better insight
into the effects of metformin on oocyte development and
ovulation in mouse models which demonstrate metabolic
and reproductive characteristics of women with PCOS.
We utilized two different leptin mutant mouse strains.
Both models, B6.Cg-m+/+ Lep
ob/J or ob/ob and the B6.V-
Lep
db/J or db/db), exhibit obesity, hyperphagia, a diabetes-
like syndrome of hyperglycemia, glucose intolerance, ele-
vated plasma insulin, and subfertility [37,38]. The ob/ob
strain does not produce endogenous leptin while the other
strain, db/db, possess a nonfunctional leptin receptor and
has elevated systemic leptin levels. We hypothesized that
metformin therapy will have an effect on oocyte matura-
tion and/or ovulatory function in ob/ob and db/db animals
compared to wild type (WT) mouse strains.
Methods
Animal studies
Animals
Eight week-old female C57BL6 wild-type (WT), leptin
deficient (B6.Cg-m+/+ Lep
ob/J, ob/ob)a n dl e p t i n
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db/J, db/db) mice (Jackson
Laboratory, Bar Harbor, ME) were housed in the animal
facility at the Massachusetts General Hospital in accor-
dance with the National Institutes of Health standards
for the care and use of experimental animals. Rooms
provided a controlled temperature range of (22-24°C) on
a 14-hour light, 10-hour dark cycle. Mice were given
food and water ad libitum. All animal procedures
described were approved by the Subcommittee on
Research Animal Care at Massachusetts General
Hospital.
In vitro cultures
Thirty six to forty hours following injection of 10 IU
pregnant mare serum gonadotropin (PMSG) (Sigma
Aldrich, ST. Louis, MO, # G4877), animals were eutha-
nized with intraperitoneal injection of Avertin 0.5 mg/ml
followed by cervical dislocation, and the ovaries of each
respective genotype were placed in DMEM supplemented
with 10% fetal bovine serum (FBS). Follicles were punctu-
red using a 28 gauge needle. For oocyte experiments,
germinal vesicle (GV) oocytes were manually denuded
with a glass pipette, pooled, and divided into DMEM
with 10% FBS with or without insulin and/or varying
concentrations of metformin. Metformin (Sigma Aldrich,
St. Louis, MO, #D150959) for in vitro cultures was dis-
solved in Dulbecco’s Modified Eagle’s Medium (DMEM,
Invitrogen 21063029, Carlsbad, CA) to 0.5 M, filter steri-
lized and diluted immediately into culture. Oocytes were
incubated at 37°C with 5% O2. Maturity was assessed by
light microscopy after 40 hours in culture. Oocytes were
classified into the following groups: germinal vesicle
oocytes (GV), germinal vesicle breakdown oocytes
(GVBD), oocytes that have completed meiosis I (M1)
(presence of first polar body) and fragmented (atretic)
oocytes. Each experiment utilized 5 mice of each geno-
type (WT, ob/ob, db/db) with 15 oocytes in each in vitro
metformin concentration group per replicate. Each
experiment was performed in quadruplicate.
For granulosa cell experiments, ovaries were placed in
phosphate buffered saline (PBS), and follicles were punc-
tured as above. After manually removing residual ovar-
ian tissue, the follicular contents were spun at 200 × g
for 5 minutes at 4°C. The supernatant was removed and
the pellets were resuspended in 1 mL of Weymouth’s
Solution (Invitrogen, Carslbad, CA, #11220035) supple-
mented with 10% FBS, Insulin-Transferrin-Selenium-A
Supplement (Invitrogen, Carslbad, CA #51300-044,
diluted 1:100), Penicillin-Streptomycin-Glutamine (Invi-
trogen, Carslbad, CA #10378, diluted 1:100) and sodium
pyruvate (Invitrogen, Carslbad, CA #11360-070 diluted
1:100). Ten microliters was mixed with 10 μLo ft r y p a n
blue and viable granulosa cells were counted with a
hemocytometer. Cells were then diluted to a concentra-
tion of 5 × 10
4/ m L ,a n d1m Lw a sp l a c e di naw e l lo fa
12 well plate. Culture medium was changed the follow-
ing day (day 1 in culture) with the same medium except
containing 1% FBS. Medium was changed every other
day thereafter and frozen and stored as below.
Progesterone assays
Medium was removed from granulosa cell cultures on
the day indicated and frozen at -20°C. Medium was then
thawed and prepared per manufacturer’sp r o t o c o l( D R G
EIA 1561, DRG International, Mountainside, NJ). Sam-
ples that contained greater than 40 ng/mL of progester-
one underwent serial dilution so that readings fell within
the standard curve of the assay (0.3 - 40 ng/mL) using a
calibrated reader at 450 nm. Granulosa cells were pooled
and subjected to treatments. Within each experiment,
each sample was run in duplicate per manufacturer’s
recommendation. Each experiment was performed in
triplicate.
Ovulation induction experiments
Six week old female mice were provided water alone or
water which contained metformin at a concentration of
0.1 mg/ml for 7 weeks (treatment group). Because the
murine estrous cycle is approximately 4.5 days, seven
weeks is equivalent to approximately 12 estrous cycles.
Metformin was added to daily water supply at a concen-
tration of 0.1 mg/mL. Based upon the average water con-
sumption of 6 mL of water per day of the C57BL6 mouse
[39], this would amount to each mouse in the treatment
group receiving a dose of metformin which approximates
a standard adult human dose of 2,000 mg per day (28 mg/
kg/day). Animals, which underwent superovulation, were
injected with PMSG 10 IU IP followed 48 hours later by
human chorionic gonadotropin (hCG) (Sigma Aldrich, St.
L o u i s ,M O ,# C G 1 0 )1 0I UI P .S i x t e e nt oe i g h t e e nh o u r s
after hCG treatment, serum glucose concentration was
analyzed using a One Touch Ultra glucometer (LifeScan,
Johnson and Johnson Subsidiary, 1000 Gibraltar Drive,
Milpitas, CA). Subsequently, animals were weighed and
euthanized with intraperitoneal injection of Avertin 0.5
mg/ml followed by cervical dislocation. Blood and oviducts
were collected. Oocytes were removed from oviducts,
counted and assessed for maturity and classified into the
previously mentioned groups. Serum total testosterone
was tested by radioimmunoassay (RIA) using the DPC
Coat-A-Count RIA kit (Diagnostics Products Corporation,
Los Angeles, CA). Experiments were performed in
triplicate.
Ovarian follicular counts
Six-week old female mice were given metformin orally as
above. At the end of the seven week period, animals were
euthanized. Ovaries were dissected and were immediately
fixed overnight in Deitricks fixative (0.34 N glacial acetic
acid, 10% formalin, 28% ethanol) for histological assess-
ment and processed for paraffin embedding. Serial sec-
tions (5 micrometers) were cut and dried for 24 hours.
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with hematoxylin for 10 minutes. Slides were counter-
stained with picric acid methyl blue for six minutes,
dehydrated, coverslipped, and allowed to dry for 24
hours. Counts of primordial (single layer of flattened
granulosa cells, preantral (single layer cuboidal granulosa
cells), preantral (2-4 granulosa cell layers) and antral (> 4
granulosa cell layers with distinct antrum visible) follicles
with visible nucleoli were performed on every fifth sec-
tion in a blinded fashion according to previously
described histomorphometric techniques [40,41]. Folli-
cles were counted in 3 independent mice per genotype.
Statistical analysis
Data were expressed as mean ± SEM of respective groups
(experiments performed in triplicate or more as indicated).
Data were analyzed using t test or two-way ANOVA with
post hoc Tukey test. P < 0.01 designated as a statistically
significant difference for ANOVA and P <0 . 0 5f o rc o m -
parison not using ANOVA.
Results
In vitro metformin treatment of mouse oocytes
There was a significant difference in the percent of oocytes
completing meiosis 1 (M1) in the 1000 μM treatment
group relative to the control group (0 μM) in WT (p =
0.01), and ob/ob (p = 0.01) mice (Figure 1). The percent
oocytes which completed M1 was 0.58 fold fewer in WT
and 0.50 fold fewer in ob/ob.T h e r ew a sn od i f f e r e n c ei n
percent oocytes completing M1 in vitro in the db/db group.
In vitro metformin exposure of mouse granulosa cell
cultures
There was no significant difference in progesterone
levels in the media of cultured granulosa cells treated
with any concentration of metfomin at any time point
assessed in any genotype relative to control (Figure 2).
In vivo metformin treatment in WT, ob/ob, and db/db
mice
Following exposure with oral metformin for seven
w e e k s( 1 2e s t r o u sc y c l e s )a n d superovulation, signifi-
cantly more mature oocytes and a greater total overall
quantity of oocytes were recovered from db/db mice.
Specifically, 1.77 fold more mature oocytes (p = 0.018)
and 1.51 fold more total oocytes overall (p = 0.04)
were obtained following superovulation of metformin
exposed db/db mice relative to controls (no treatment)
(Figure 3C). There was no difference in the quantity
and proportion of mature oocytes obtained after super-
ovulation of metformin exposed WT and ob/ob mice
(Figure 3A, 3B). Animal weight (Figure 3D) and serum
testosterone levels (Figure 3F) were unchanged during
the metformin treatment course for any genotype.
Blood glucose levels did not differ in response to met-
formin treatment in any genotype (Figure 3E). Both
ob/ob and db/db mice demonstrated significantly
greater baseline testosterone levels, serum glucose
levels, and body mass (weight) than WT animals (p <
0.01).
Gross ovarian anatomy
This analysis revealed that the control db/db mice
demonstrated a two fold greater total non atretic folli-
cular count relative to control WT animals (p = 0.01)
(Figure 4D). Overall, animals treated with metformin
did not demonstrate any change in the total follicle
numbers or number in any specific follicular stage in
any genotype studied compared to their respective
controls.
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Figure 1 Effect of metformin on in vitro oocyte maturation. The vertical axis represents the percent of oocytes which completed meiosis I
(MI) in culture. The horizontal axis shows in vitro metformin concentration (micromolar [μM]). Each experiment utilized 5 mice for each genotype
(WT, ob/ob, db/db) with 15 oocytes in each in vitro metformin concentration group per replicate. Each experiment was performed in
quadruplicate. Error bars are SEM. Oocytes treated with metformin concentration of 1000 μM demonstrated a reduction in percent oocytes
which completed MI compared to control (0 μM) in WT and ob/ob. Asterisks indicate statistical significance of p < 0.05 for WT and ob/ob
genotypes following comparison (* and ** p = 0.01, t test).
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Figure 3 Reproductive and metabolic effects of oral metformin pretreatment during superovulation. For A-C, C = control, MF =
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fragmented oocyte. Experiments were performed in triplicate. Error bars are SEM. A statistically significant increase in the quantity of ovulated
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control (* denotes p = 0.018 and ** denotes p = 0.04, t test) (C). ob/ob and db/db mice demonstrated greater respective body mass (D) and
testosterone levels (F) compared to WT mice. Metformin did not have an appreciable effect on any metabolic measure in any genotype relative
to control (D, E, F). Different designated letters among genotypes in D, E, and F indicate statistical difference with p < 0.01 (ANOVA).
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Distinct features in women with PCOS, insulin resis-
tance and compensatory hyperinsulinemia, lead to
hyperandrogenemia due to increased ovarian androgen
production and decreased production of sex hormone
binding globulin [42,43]. Since hyperinsulinemia has
been implicated as a significant cause of anovulation,
many investigators hypothesized that a reduction of sys-
temic insulin serum levels would result in an improve-
ment of ovulatory function and overall fecundity in
PCOS women. Initial studies investigating the use of
metformin in PCOS demonstrated a beneficial role of
metformin as an ovulation induction agent compared to
placebo, clompihene citrate (CC), and CC and metfor-
min combined [16]. However, two subsequent large,
prospective, double blind studies did not demonstrate
any benefit for metformin treatment in women with
PCOS in terms of ovulation rate and pregnancy out-
come [44,45]. Despite a long track record of metformin
use in type 2 diabetes, it still remains unclear whether it
provides a beneficial reproductive effect as an adjuvant
therapy in women with PCOS. Furthermore, if there is a
beneficial reproductive effect of metformin, it is unclear
whether it acts locally at the level of the ovary, pituitary,
hypothalamus, or on a more systemic level. In this
study, we have demonstrated for the first time, that met-
formin confers significant in vitro and in vivo effects on
oocyte maturation in mouse strains with metabolic and
reproductive characteristics of PCOS. Specifically, we
demonstrate a reduction in the completion of meiosis 1
by oocytes in vitro following metformin exposure in
WT and ob/ob mice, and an increase in the yield of
mature oocytes and total overall oocytes following con-
tinuous dietary metformin for 7 weeks prior to supero-
vulation in a db/db in vivo model.
We hypothesized that treatment with the insulin sen-
sitizer, metformin, would have an impact on oocyte
maturation and/or ovulation in a PCOS-like mouse
s t r a i nw i t hah y p e r i n s u l i n e m i ca n da n o v u l a t o r yp h e n o -
type. Previous studies examining the effects of metfor-
min, have focused on specific compartments of the
ovary, namely the oocyte and granulosa cells in WT ani-
mals (congenic mice and outbred strains of cows and
pigs), with normal ovulatory function [30-32]. In vitro
studies have demonstrated direct effects of metformin
on the ovary, which involve inhibition of basal and insu-
lin stimulated granulosa cell P450 aromatase via MEK/
ERK (MAPK kinase) activation [46]. Similar to pre-
viously published studies detailing an inhibitory effect of
metformin on in vitro oocyte maturation [30,31], the
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Figure 4 Ovarian follicular counts (non atretic) following in vivo metformin exposure. Horizontal axis indicates follicle stage. Follicle counts
were performed in mice (N = 3) who underwent 7 weeks of oral metformin treatment or no treatment (control) (A, B, C). C = control, MF =
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reduced in vitro maturation of the mouse oocyte. Speci-
fically, meformin exerted a significant reduction of
maturation of oocytes derived from WT and ob/ob
mice, but not in db/db mice. Notably, the in vitro con-
centration of metformin which demonstrated this find-
ing was at the highest concentration, and may represent
an extremely elevated in vivo serum level which sur-
passes the typical human metformin dose of 2000 mg
daily dose (approximately 10 μM). These collective find-
ings raise the possibility that this effect may be an arti-
fact of toxicity of the high levels of metformin.
Alternatively, these findings may be the result of in vitro
conditions, which may not be directly applicable to in
vivo conditions.
Based upon previous data [47] which demonstrated an
antiapoptotic effect of metformin on luteinized granu-
losa cells in PCOS patients undergoing IVF, it may be
expected that metformin treatment would result in ele-
vated progesterone levels in conditioned media from
cultured granulosa cells derived from both transgenic
mouse models which share PCOS characteristics. How-
ever, there was no obvious effect of increasing doses of
metformin on progesterone levels in conditioned media
derived from granulosa cells in any genotype. Therefore,
it can be inferred that there was no significant change
in cell number. The differences in our results may be
attributed to species to species variability in response to
metformin or may reflect the complexity of steroidogen-
esis, which likely involves multiple pathways indepen-
dent of those regulated by metformin.
In vivo studies examined the chronic effects of metfor-
min pretreatment on oocyte development and ovulatory
performance in WT, ob/ob and db/db mouse strains
during superovulation. With the use of 0.1 mg/ml met-
formin in drinking water (approximate to human dose
of 2000 mg per day), these experiments demonstrated
that metformin significantly increased the number of
mature oocytes ovulated by 1.77 fold (p = 0.018) and
the total overall number of oocytes released by 1.51 fold
(p = 0.04) in db/db mice during superovulation. Inter-
estingly, this same result was not observed in the ob/ob
mouse strain, which shares many phenotypic similarities
(obesity, hyperglycemia, hyperinsulinemia, and infertility
with anovulation). In contrast to the ob/ob mouse,
which lack endogenous leptin production, the db/db
mouse has elevated systemic leptin levels. An explana-
tion of the results seen only in the db/db strain may be
due to a possible effect of metformin on this animal’s
endogenously elevated leptin levels. Notably, there are
preliminary data describing the reduction of leptin by
metformin in women with PCOS [48]. However, the fact
that the db/db mice lack a functional cognate receptor
leptin receptor (long isoform) would imply that any
change incurred by a decrease in leptin may be indica-
tive of leptin eliciting a response through the less char-
acterized short form of the OB receptor or via an
unrecognized alternative receptor.
G i v e nt h ek n o w nr o l eo fh y p e r i n s u l i n e m i aa n dh y p e r -
androgenemia in PCOS anovulation, it may also be initi-
ally inferred that the metformin treated db/db genotype
displayed improved glucose control and weight loss com-
pared to other mouse strains. However, there were no
significant differences in weight, glucose, or testosterone
levels in any metformin treated mouse strain compared
to controls. This observation in the db/db mouse may
signify a more pronounced, yet less detectable intrafolli-
cular effect of hyperinsulinemia in this transgenic geno-
type. In line with prior observations of dysfunctional
steroidogenesis and folliculogenesis in PCOS [49], cor-
rection of this metabolic derangement with the insulin
sensitizer, metformin, may have established a more favor-
able intrafollicular insulin environment and may have
optimized ovulatory performance, resulting in an
improvement in the production of mature oocytes during
superovulation in the db/db strain. Several authors have
recently publishedf i n d i n g sw h i c hs u p p o r tap o s s i b l e
direct impact of metformin on the ovary. Stimulation of
lactate production and activation of AMPK in granulosa
cells by this compound has been proposed as a mechan-
ism of improving follicular and oocyte development [50].
Additionally, the findings of Palomba et al. demonstrate
a significant effect of metformin on intrafollicular insulin
growth factor 2, several insulin growth factor binding
proteins, estradiol, and androgen levels in women with
PCOS [51].
Although there is not a single ideal animal model for
PCOS, several reproductive and metabolic features com-
monly observed in PCOS are present in the animal
models utilized in the present study. As highlighted pre-
viously, there are other additional mouse and rat models
which have been utilized to study PCOS [52]. Unfortu-
nately, some primarily possess metabolic traits, others
demonstrate only reproductive characteristics, while
others possess some combination of both [37,38,52,53].
As is true with other models, the mouse strains used in
this study do not perfectly simulate human PCOS. To
this end, one model will not be completely representa-
tive of all human PCOS phenotypes. Investigation in
many different models will be likely required to gain a
more comprehensive understanding of the metabolic
and reproductive aspects of this syndrome. Since the ob/
ob and db/db mice share both reproductive and meta-
bolic characteristics of women with PCOS, it was most
appropriate to utilize these strains to investigate the
potential reproductive effects of metformin in a hyperin-
sulienmic and anovulatory in vivo model. Although the
exact mechanism of metformin has not been elucidated,
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inhibitory effects of metformin at the level of the oocyte
have been inferred from various mammalian studies
using the AMPK activator (AICAR) and AMPK inhibi-
tor Compound C [30-32]. Unfortunately, it is difficult to
directly assess the discreet physiologic role of metformin
AMPK activation in reproduction in this model. In
future studies, it may be possible to assess the role of
the metformin AMPK pathway in another model since a
group of investigators have demonstrated that the kinase
LKB1 mediates glucose homeostasis in liver and the
therapeutic effects of metformin [54]. In order to defini-
tively characterize the function of metformin via the
AMPK pathway, the use of the LKB1 deficient mouse
may provide additional insight into AMPK mediated
local and systemic effects of metformin from a meta-
bolic and reproductive standpoint.
Due to the wide variation of metabolic and reproduc-
tive characteristics in women with the polycystic ovarian
syndrome, it has become a difficult task to identify if
any PCOS phenotype may benefit from metformin. The
unpredictable extent to which a specific end organ is
affected by insulin resistance or hyperinsulemia (e.g.
ovary of a woman with PCOS) is likely contributory to
the inconsistent results of previous studies examining
metformin use in PCOS [54]. Given the continued
uncertainty regarding the clinical reproductive benefit of
metformin use for PCOS associated infertility, a study
such as this, can assist the field in determining whether
this adjuvant therapy is of tangible benefit in clinical
practice. In the hyperinsulinemic and hyperandrogenic
anovulatory leptin ob/ob and db/db mutant mouse
strains, no significant effect of metformin was observed
at physiologic levels in vitro at the level of oocyte or
granulosa cells to increase oocyte maturity or progester-
one production respectively. As hypothesized, a benefi-
cial in vivo effect was demonstrated in the db/db strain
as seen by an improvement of the yield of mature
oocytes during superovulation. When considering our
findings, it may be reasonable to speculate that metfor-
min may act to optimize oocyte development and pro-
duction by the local and/or systemic reduction of
hyperinsulinemia, androgen and leptin production, as
well as by the reduction of inappropriately high intrafol-
licular estradiol levels (seen in PCOS patients) by
attenuation of aromatase activity as highlighted pre-
viously [46,49]. In light of recent findings which suggest
that metformin may act via an insulin dependent
mechanism in the human ovary, this treatment may
confer a significant effect on oocyte development and
ovulatory performance in the dbdb m o u s ea n das u b s e t
of similarly hyperleptinemic and hyperinsulinemic
women with PCOS [55], Additionally, the larger follicu-
lar endowment of db/db mice, compared to other
genotypes, may also contribute an unknown influence
on oocyte maturation and development during
superovulation.
Conclusions
In summary, by using transgenic mouse models with
characteristics of PCOS, we have demonstrated a signifi-
cant in vivo reproductive effect of metformin use in a
specific mouse strain. These findings may imply that a
specific subset of women with the PCOS reproductive
phenotype may potentially benefit from metformin, while
t h em a j o r i t yw i t ht h i ss y n d r ome will not. Additionally,
the observed in vivo effects of metformin in the hyperlep-
tinemic db/db strain may infer that a subset with the
PCOS reproductive phenotype characterized by hyperin-
sulinemia, anovulation, and hyperleptinemia may be
more responsive to metformin than those without ele-
vated leptin levels. With the use of a transgenic mouse
strain such as db/db, our findings demonstrate a possible
role of metformin to optimize ovulatory performance
during superovulation in mice with a specific reproduc-
tive and metabolic phenotype. To this end, future studies
utilizing the db/db mouse strain and other PCOS-like
murine models will provide the foundation for future
investigation to clearly determine the utility of metformin
treatment in the human model of PCOS.
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